Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03493282 · ClinicalTrials.gov registry record · Phase 1
Effect of CT1812 Treatment on Brain Synaptic Density
A Phase 1 study of Alzheimer Disease, sponsored by Cognition Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT03493282 is a Phase 1 study of Alzheimer Disease that has completed, run by Cognition Therapeutics. The registered enrollment target is 43 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03493282, a Phase 1 study of Alzheimer Disease, has completed, sponsored by Cognition Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Active Treatment- CT1812 100 mg
- DRUG Active Treatment- CT1812 300 mg
Study Locations (1)
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-03-28 |
| Est. Completion | 2020-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03493282
The ClinicalTrials.gov registry entry for NCT03493282 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The listed sponsor is Cognition Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03493282 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT03493282 about?
NCT03493282 is a clinical study titled "Effect of CT1812 Treatment on Brain Synaptic Density". Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.
What is the current status of trial NCT03493282?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2018-03-28. Estimated completion is 2020-10-16.
What conditions does trial NCT03493282 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT03493282?
The interventions under investigation include: Placebo (DRUG), Active Treatment- CT1812 100 mg (DRUG), Active Treatment- CT1812 300 mg (DRUG).
Who is sponsoring clinical trial NCT03493282?
This trial is sponsored by Cognition Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03493282 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.